Executive interview – Verona Pharma at EKF 2019

Published on 9 December 2019

In this interview, Dr David Ebsworth, non-executive chairman of Verona Pharma, provides an overview of the company and its pipeline of assets. He goes on to discuss plans for the pivotal Phase III development of ensifentrine, the company’s lead product, as well as the regulatory and commercial strategy in Verona Pharma’s core markets. He finishes the interview by explaining how the company is funded and upcoming catalysts investors should pay attention to.

Share this with friends and colleagues